{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:45:51Z","timestamp":1792622751056,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ijantimicag.2020.106106","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T02:37:12Z","timestamp":1595644632000},"page":"106106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Fosfomycin for bacterial prostatitis: a review"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2448","authenticated-orcid":false,"given":"Alex C.F.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-8570","authenticated-orcid":false,"given":"Nathan P.","family":"Beahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106106_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0022-5347(05)66541-X","article-title":"Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index","volume":"165","author":"Nickel","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0002","doi-asserted-by":"crossref","unstructured":"Nickel JC. Prostatitis. Can Urol Assoc J2011:306\u201315.","DOI":"10.5489\/cuaj.11211"},{"issue":"3015\u201322","key":"10.1016\/j.ijantimicag.2020.106106_bib0003","first-page":"3025","article-title":"Treatment of prostatitis","volume":"61","author":"Stevermer","year":"2000","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0006","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1128\/AAC.00721-09","article-title":"Susceptibility of urinary tract bacteria to fosfomycin","volume":"53","author":"Maraki","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0007","first-page":"268","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0008","series-title":"Canadian Antimicrobial Resistance Surveillance System \u2013 update 2018","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0009","series-title":"Antibiogram 2017","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0010","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/infdis\/jiv279","article-title":"The rise of fluoroquinolone-resistant Escherichia coli in the community: scarier than we thought","volume":"212","author":"Spellberg","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0011","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/QCO.0000000000000314","article-title":"The management of multidrug-resistant Enterobacteriaceae","volume":"29","author":"Bassetti","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0012","doi-asserted-by":"crossref","first-page":"E580","DOI":"10.9778\/cmajo.20180039","article-title":"Emerging antimicrobial resistance among Escherichia coli strains in bloodstream infections in Toronto, 2006\u20132016: a retrospective cohort study","volume":"6","author":"Mineau","year":"2018","journal-title":"CMAJ Open"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0013","first-page":"25","article-title":"Antibiotics and bacterial resistance in the 21st century","volume":"6","author":"Fair","year":"2014","journal-title":"Perspect Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.urology.2017.08.070","article-title":"Impact of allergy and resistance on antibiotic selection for recurrent urinary tract infections in older women","volume":"113","author":"Malik","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0015","first-page":"418","article-title":"FDA issues new fluoroquinolone safety warnings and prescribing restrictions","volume":"69","author":"Peters","year":"2016","journal-title":"S D Med J S D State Med Assoc"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0016","doi-asserted-by":"crossref","first-page":"a816","DOI":"10.1136\/bmj.a816","article-title":"FDA adds \u2018black box\u2019 warning label to fluoroquinolone antibiotics","volume":"337","author":"Tanne","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0018","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim-sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ Can Med Assoc J J Assoc Med Can"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jiac.2016.01.010","article-title":"Resurgence of an old companion","volume":"22","author":"Sastry","year":"2016","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cit704","article-title":"Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0021","first-page":"969","article-title":"[Transference of antibiotics into prostatic tissues: sampling method by transurethral resection for the measurement of the concentration of antibiotics in prostatic tissue]","volume":"32","author":"Takasaki","year":"1986","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/and.13021","article-title":"Pharmacodynamic and pharmacokinetic studies and prostatic tissue distribution of fosfomycin tromethamine in bacterial prostatitis or normal rats","volume":"50","author":"Fan","year":"2018","journal-title":"Andrologia"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02560-17","article-title":"Pharmacokinetics and pharmacodynamics of fosfomycin and its activity against extended-spectrum-\u03b2-lactamase-, plasmid-mediated AmpC-, and carbapenemase-producing Escherichia coli in a murine urinary tract infection model","volume":"62","author":"Zykov","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0024","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0974-7796.148585","article-title":"Increasing antimicrobial resistance among uropathogens: is fosfomycin the answer?","volume":"7","author":"Sultan","year":"2015","journal-title":"Urol Ann"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0026","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.26.5.789","article-title":"Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa","volume":"26","author":"Takahashi","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0027","first-page":"943","article-title":"Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic Gram-negative bacilli","volume":"12","author":"Chin","year":"1986","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s101560200004","article-title":"Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay","volume":"8","author":"Okazaki","year":"2002","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0029","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jmii.2010.08.012","article-title":"Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan","volume":"44","author":"Liu","year":"2011","journal-title":"J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0031","first-page":"142","article-title":"In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon","volume":"60","author":"Araj","year":"2012","journal-title":"J Med Liban"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0032","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ijcp.12608","article-title":"Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities","volume":"69","author":"Saltoglu","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0033","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s40265-013-0143-y","article-title":"Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0034","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0035","series-title":"Antimicrobial wild type distributions of microorganisms (fosfomycin). Version 5.26","year":"2019"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0036","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki280","article-title":"Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-\u03b2-lactamase gene from Saudi Arabia","volume":"56","author":"Guerin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0037","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for treatment of prostatitis: new tricks for old dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0038","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00019048-200009090-00004","article-title":"Treatment of a complicated vancomycin-resistant enterococcal urinary tract infection with fosfomycin","volume":"9","author":"Shrestha","year":"2000","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0039","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/jac\/dkz015","article-title":"Oral fosfomycin for the treatment of chronic bacterial prostatitis","volume":"74","author":"Karaiskos","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0040","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.02611-15","article-title":"Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis","volume":"60","author":"Los-Arcos","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0041","doi-asserted-by":"crossref","first-page":"e00493","DOI":"10.1016\/j.idcr.2019.e00493","article-title":"Chronic prostatitis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli managed using oral fosfomycin \u2013 a case report","volume":"15","author":"Almeida","year":"2019","journal-title":"IDCases"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0042","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2169\/internalmedicine.53.3098","article-title":"Fosfomycin for the treatment of prostate infection","volume":"53","author":"Hagiya","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0043","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","article-title":"Persistent extended-spectrum \u03b2-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline","volume":"45","author":"Cunha","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0044","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijantimicag.2016.02.009","article-title":"Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: successful treatment with prolonged fosfomycin therapy","volume":"47","author":"Gian","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijantimicag.2008.03.014","article-title":"Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis","volume":"32","author":"Naber","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0046","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1086\/652861","article-title":"Treatment of bacterial prostatitis","volume":"50","author":"Lipsky","year":"2010","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0047","article-title":"Antimicrobial therapy for chronic bacterial prostatitis","volume":"8","author":"Perletti","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0048","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14787210.2019.1573669","article-title":"Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?","volume":"17","author":"Dimopoulos","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0049","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/aja.2012.40","article-title":"Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis","volume":"14","author":"Zhao","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0050","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1513\/AnnalsATS.201603-194FR","article-title":"Microbial biofilms in pulmonary and critical care diseases","volume":"13","author":"Boisvert","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0051","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin \u2013 back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.ijantimicag.2020.106106_bib0052","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) vs piperacillin-tazobactam (PIP-TAZ) for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP): ZEUS, a phase 2\/3 randomized trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00775-17","article-title":"Pharmacokinetics, safety, and tolerability of single-dose intravenous (ZTI-01) and oral fosfomycin in healthy volunteers","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0054","article-title":"Intravenous fosfomycin: an assessment of its potential for use in the treatment of systemic infections in Canada","volume":"2018","author":"Zhanel","year":"2018","journal-title":"Can J Infect Dis Med Microbiol J Can Mal Infect Microbiol Med"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jiac.2015.05.014","article-title":"Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases","volume":"21","author":"Ishikawa","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0056","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO\u2022SENS study revisited","volume":"39","author":"Kahlmeter","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0057","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/jac\/dkq346","article-title":"Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli","volume":"65","author":"Oteo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0058","doi-asserted-by":"crossref","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","article-title":"Fosfomycin: mechanism and resistance","author":"Silver","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ijantimicag.2020.106106_bib0059","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drup.2010.05.002","article-title":"Resistance to polymyxins: mechanisms, frequency and treatment options","volume":"13","author":"Falagas","year":"2010","journal-title":"Drug Resist Updat"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:28Z","timestamp":1760377048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0924857920302892"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106106","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fosfomycin for bacterial prostatitis: a review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106106"}}